• Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported data showing that once-daily olodaterol, a long-acting beta2-agonist, as a maintenance treatment in chronic obstructive pulmonary disease provided a significant and identical increase in the lung function parameter FEV1 over a 24-hour period compared to twice-daily treatment, when delivered via the Respimat inhaler. Data were presented at the American Thoracic Society meeting in San Francisco.

• Janssen Research & Development, of Raritan, N.J., a unit of Johnson & Johnson, reported findings showing that subcutaneous induction regimens of anti-TNF-alpha therapy Simponi (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis who had previously failed or were intolerant to conventional agents. More than 50 percent of patients in each of the two Simponi dosing groups achieved clinical response at week six, the primary endpoint of the study, which was significantly more than those in clinical response after getting placebo. Data were presented at Digestive Disease Week in San Diego.

No Comments